Learning objectives

1. Implement evidence-based risk stratification strategies to optimize thrombosis prevention and management in ACS, AF, and SSP:

• Apply CHA₂DS₂-VASc and HAS-BLED scoring to accurately identify AF patients at high risk of stroke and determine appropriate anticoagulation therapy​.
• Utilize validated risk assessment tools, such as GRACE and TIMI scores, to guide individualized antithrombotic treatment decisions in ACS and SSP​.
• Improve detection and management of asymptomatic AF (AAF) and undiagnosed stroke-risk patients, ensuring timely initiation of anticoagulation​.

2. Individualize antithrombotic therapy selection and dosing to maximize efficacy while mitigating bleeding risks in ACS, AF, and SSP:

• Optimize DOAC dosing and selection to ensure stroke prevention without increasing bleeding risk, reducing underuse and inappropriate substitution with antiplatelets​.
• Address barriers to adherence and improve patient engagement in shared decision-making, ensuring informed choices about anticoagulation​.
• Reduce inappropriate modifications of anticoagulant therapy due to bleeding concerns, ensuring alignment with clinical guidelines and real-world outcomes​.

3. Evaluate the role of emerging Factor XI inhibitors and their potential to redefine anticoagulation strategies in ACS, AF, and SSP:

• Assess the mechanism, safety, and efficacy of FXI/FXIa inhibitors compared to DOACs and VKAs, leveraging data from ongoing Phase III trials such as LIBREXIA.
• Identify patient populations who may benefit most from FXI inhibition, including those at high thrombotic risk but contraindicated for current anticoagulants due to bleeding risk​.
• Translate new clinical trial findings into practical considerations for future anticoagulation protocols, ensuring preparedness for emerging therapies in clinical practice​.

This program is supported by an independent education grant from Bristol Myers Squibb and Johnson and Johnson. This online education program has been designed for healthcare professionals globally.

Continuing Education Information

This continuing education activity will be provided by Current Concepts Institute (CCI) and MedAll. Physicians, Nurse Practitioners, and Physician Assistants will be eligible for AMA PRA Category 1 Credit™ ; Nurses for ANCC Contact Hours. A statement of participation is available for other healthcare professionals.

Disclosures
Below is a listing of all individuals who are involved in the planning and implementation of this accredited continuing education activity. All relevant financial relationships listed for these individuals have been mitigated.​

Dr Jennifer Rymer has disclosed financial relationships within the past 24 months with the following ineligible companies: Chiesi, Idorsia Pharmaceuticals, Abbott, serving in advisory or investigator roles. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. Dr. Jennifer Rymer does not intend to reference any unlabeled or unapproved uses of products during the presentation.

Dr. Siddharth M. Patel has disclosed financial relationships within the past 24 months with the following ineligible companies. He has received consulting fees from Janssen. Through his institution, he has also received research grants from Abbott, Abiomed, Amgen, Anthos Therapeutics, ARCA Biopharma, and AstraZeneca to the TIMI Study Group. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.

Dr. Christian T. Ruff has disclosed financial relationships within the past 24 months with the following ineligible companies. He has received grants through his institution from Anthos, AstraZeneca, Daiichi Sankyo, Janssen, and Novartis. He has also received honoraria for participation on scientific advisory boards and consulting from Daiichi Sankyo, Janssen, Pfizer, Anthos, Bayer, and Bristol Myers Squibb. These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education. His presentation includes reference to non-FDA uses of drug products and/or devices and their unlabelled indications. We will disclose to the audience when this discussion takes place.

CCI staff, MedAll staff, and all planners and reviewers have no relevant financial relationships with ineligible companies to disclose.​

Activity Accreditation for Health Professions

Physicians

0.25 AMA PRA Category 1 Credits™ are available for this activity.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and MedAll Education. Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.

Current Concepts Institute designates this online activity a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This continuing education activity is active starting November 1st 2025 and will expire on March 31st 2026. Estimated time to complete this activity: 15 minutes.

Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Participation Costs
There is no cost to participate in this program.